Skip to content

CBL-514

Also called Caliway Biopharmaceuticals' injectable small-molecule lipolysis agent that triggers fat-cell apoptosis; being developed as a non-surgical fat-reduction injection. Not a peptide and not a GLP-1 drug

A small-molecule injectable that was designed to remove fat cells locally rather than shrink them.

  • TypeSmall molecule
  • FormInjectable
  • Researched forMetabolic & Fat Loss

Where to get CBL-514

Disguised Alpha
Injectable
Code CAMERON

21+ to enter. The only form sold. Research compound, not approved for human use.

Shop injectable at Disguised Alpha

The short version

  • Why people research itLocalized abdominal fat reduction in randomized human trials.
  • What the evidence isThree published trials, one of them placebo-controlled with a clear primary endpoint.
  • What to watchHard lumps, spreading redness or heat at the site.

How CBL-514 works

The mechanism predicts a local, slow and imaging-visible effect, which is what was found. Apoptosis rather than lysis should avoid the inflammatory burst of detergent-style injections, and the clearance of dead adipocytes over weeks matches the 4- and 8-week follow-up curve.

It is reported to induce apoptosis in adipocytes: the cells die in a controlled way and the contents are cleared over weeks, which is different from a detergent injection that bursts cells and inflames the area. In the three published human trials the drug was injected into the abdominal fat layer by clinicians in a grid pattern, and the readouts were ultrasound fat thickness and volume, then MRI and rating scales. The effect is local: the evidence is for reduced abdominal fat at the injected site, not body-wide weight loss.

  • Injectable

On the goal map: Direct lipolysis & adrenergic drive (Lose fat)

Research on CBL-5145 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: Human (randomized phase II and phase 2b trials, abdominal subcutaneous fat).

Human clinical evidence

  • Three published trials, one of them placebo-controlled with a clear primary endpoint. In the 2025 phase II (76 adults, randomized 2:1 to drug or placebo). A 2026 phase 2b in 108 adults added clinician and patient scales and MRI (Lorenc 2026). The first phase IIa, found the higher levels reduced fat volume and thickness and were well tolerated (Goodman 2022).

  • What they do not show. All three were sponsor-run programs with clinician-delivered injections in a mapped abdominal grid, assessed by imaging. The endpoint is local fat volume, not body weight, metabolic health or durability beyond the short follow-up, and the 2025 trial was single-blind.

Correlative data

  • No clinical practice record outside the trials. The compound is investigational. People using vendor vials are not in a registry and are not performing the clinic procedure.

How the mechanism reads

  • The mechanism predicts a local, slow and imaging-visible effect, which is what was found. Apoptosis rather than lysis should avoid the inflammatory burst of detergent-style injections, and the clearance of dead adipocytes over weeks matches the 4- and 8-week follow-up curve. The prediction that matters most is the one trials cannot settle at home: injection depth, grid spacing and sterility decide whether the drug reaches fat cells at all.

    Mechanistic
  • Predicted downside. Local swelling, bruising and tenderness are the expected injection-site effects, and a mass cell-death event should be watched through liver enzymes and triglycerides. Neither was a reported problem in the abstracts read, but those were small, short, supervised studies.

    Mechanistic

CBL-514 safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Treating anywhere other than a mapped subcutaneous fat area: the trial effect depends on injection depth and grid.
  • A liver condition or raised liver enzymes, since the body clears the contents of killed fat cells through the liver.
  • Raised triglycerides or fatty liver, because mass fat-cell death releases lipid.
  • An active skin infection or poor skin-healing over the target area.
  • Pregnancy, breastfeeding or anything that makes self-injection into fat unsafe.

What’s expected

  • Local swelling, bruising and tenderness are the effects that follow from injecting a cell-killing agent.
  • Slow change in fat thickness over weeks as dead cells are cleared.

Watch for

  • Hard lumps, spreading redness or heat at the site.
  • Skin darkening, dimpling or tissue breakdown.
  • Yellowing of the skin or dark urine.

Labs that tell you it’s working

  • Lipid Panel: triglycerides are the marker for released lipid.
  • Comprehensive Metabolic Panel: liver enzymes show clearance load.
  • hs-CRP: tracks local inflammation spill.

Injectable that induces fat-cell apoptosis; the trial record is supervised clinic delivery, so every risk here is about procedure and clearance load. PMID 40037659 PMID 35709509 PMID 42159040

Bloodwork to runHow you would know it is working: 6 tests in one order, code CAMERON

CBL-514 FAQ4 common questions

Is CBL-514 approved for human use?
No. CBL-514 is a research compound.
What is CBL-514 researched for?
Localized abdominal fat reduction in randomized human trials.
Which labs show whether it's doing anything?
Lipid Panel; Comprehensive Metabolic Panel; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for CBL-514: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what CBL-514 is. Skool covers how it is run.

Free on this page

What CBL-514 is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What CBL-514 is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool